Funding Received
$49.1 Million in 3 Rounds from 8 Investors
Most Recent Funding
$36 Million Series B on April 16, 2014
Headquarters:
Boston, MA
Description:
Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.
Categories:
Biotechnology
Website:
http://www.epirusbiopharma.com

Company Details

Update

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Current Team (10)

Update

Board Members and Advisors (6)

Update

Investors (8)

Update

Offices/Locations (1)

Update
  • EPIRUS Biopharmaceuticals

    699 Boylston Street

    11th Floor

    Boston, MA 02116

    USA

Images (2)

Update
  • Gzgrslsi1ekov9btc0fm
  • F1f1225ea4bc1d13b4ca965e933017e3